Magdalena Sánchez

CMV-specific T-cell immunity in solid organ transplant recipients at low risk of CMV infection. Chronology and applicability in preemptive therapy.

E. Cordero, E. Lage, M. Gentil, 2017, The Journal of infection.

Viral load, CMV‐specific T‐cell immune response and cytomegalovirus disease in solid organ transplant recipients at higher risk for cytomegalovirus infection during preemptive therapy

E. Cordero, M. Gentil, P. Pérez-Romero, 2014, Transplant international : official journal of the European Society for Organ Transplantation.

Clinical impact of neutropenia related with the preemptive therapy of CMV infection in solid organ transplant recipients.

E. Cordero, J. Cisneros, E. Lage, 2014, The Journal of infection.

[Descriptive study of infectious complications in 109 consecutive liver transplant recipients].

J. Pascasio, E. Cordero, J. Cisneros, 2009, Enfermedades infecciosas y microbiologia clinica.

First Face Composite-Tissue Transplant Recipient Successfully Treated for Cytomegalovirus Infection with Preemptive Valganciclovir Treatment

T. Gómez-Cía, E. Cordero, P. Infante-Cossio, 2011, Antimicrobial Agents and Chemotherapy.

Quantitative pp65 antigenemia in the diagnosis of cytomegalovirus disease: prospective assessment in a cohort of solid organ transplant recipients.

M. Bernabeu-Wittel, J. Pachón, J. Cisneros, 2005, The Journal of infection.

Preemptive therapy for the prevention of cytomegalovirus disease following heart transplantation directed by PP65 antigenemia.

J. Cisneros, R. Hinojosa, E. Lage, 2003, Transplantation proceedings.